Roche's IMpassion130 Is First Positive Phase III Immunotherapy Study In Triple Negative Breast Cancer

Phase III IMpassion130 study showed Tecentriq plus Abraxane significantly reduced the risk of disease worsening or death in people with metastatic triple negative breast cancer.

Mammography test
Tecentriq posts positive results in triple negative breast cancer • Source: Shutterstock

Roche's IMpassion130 combining its flagship cancer immunotherapy Tecentriq with chemo has met its endpoints, making it the first positive Phase III immunotherapy study in triple negative breast cancer and adding to the rising amount of positive data involving the PD-L1 inhibitor.

More from Immuno-oncology

More from Anticancer